An innovative heart stent developed in India has received significant international recognition for its performance in high-risk patients. This new generation stent, named Supraflex Cruz, has demonstrated a lower failure rate compared to the leading US competitor, Xience. The findings were presented at a prominent global cardiology conference that concluded recently in San Francisco.
Dr Upendra Kaul, a distinguished cardiologist and the Chairman and Dean of Batra Hospital in Delhi, shared the results from a comprehensive trial known as TUXEDO-2. This trial was conducted across 66 cardiology centers in India and specifically targeted a challenging patient demographic, including those with diabetes and advanced multi-vessel disease. Notably, 80 percent of the participants presented with triple vessel disease, according to Dr Kaul, who oversaw the trial.
The trial”s results were overwhelmingly favorable for the Indian-made stent, showing that Supraflex Cruz was non-inferior to the established international standard. The data indicated that the Indian device had a significantly lower rate of Target Lesion Failure (TLF), a metric that encompasses severe outcomes such as cardiac death, target vessel myocardial infarction, and the necessity for additional clinical procedures.
Additionally, Dr Kaul noted that the Supraflex Cruz stent, produced by a company based in Surat, recorded a numerically lower incidence of heart attacks within one year following the procedure. The positive outcomes of the trial were praised during the conference, highlighting the technical prowess present in Indian medical device manufacturing.
The successful execution of this trial was achieved under the collaborative leadership of Dr Kaul, Co-Chairman Dr Sripal Bangalore, and Project Director Dr Priyadarshini Arambam. Their collective efforts have positioned the Indian stent as a competitive player in the global market, potentially improving patient outcomes for those with complex heart conditions.
